Phase 2 Liver Cancer Trial, Recruiting NCT06526338 Sponsor: Robert C. Martin Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06526338
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older at the time of signing the consent form.
  • You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC), confirmed either by imaging scans using standard criteria or by a tissue biopsy.
  • Your treatment plan includes a procedure to destroy the tumor (using radiofrequency or microwave ablation) or surgery to remove it, with the goal of curing the cancer.
  • Your liver cancer is considered to have an intermediate, high, or very high chance of coming back after treatment.
  • Your liver cancer is only in the liver, with no tumors larger than 1 cm found elsewhere in the body.
  • You are generally able to carry out daily activities and care for yourself (as rated by a standard medical scale called ECOG performance status 0–1).
  • If you have had or currently have hepatitis C, you must have finished hepatitis C treatment at least 1 month before the start of the trial.
  • If you have hepatitis B, it must be well controlled, with a low virus level in your blood, and you may need to be on antiviral treatment — specific details should be confirmed with the trial site.
  • Your kidneys, liver, and other organs are working well enough, as shown by blood tests taken within 14 days before the trial starts.

Who may not be able to join:

  • You have a known allergy to shellfish, crabs, crustaceans, or any ingredient used in this trial.
  • You currently have an active infection that requires treatment with medication.
  • You have been diagnosed with an immune system deficiency, or you are currently taking high-dose steroid medication (more than 10 mg of prednisone per day or equivalent), or any other medication that suppresses your immune system within 7 days before the trial starts.
  • You have an active autoimmune disease (where your immune system attacks your own body) that has needed medical treatment within the past 2 years — note that simple hormone replacement therapy such as thyroid medication or insulin does not count as this type of treatment.
  • You have previously received an organ or tissue transplant from another person.
  • You have a history of certain lung conditions, including idiopathic pulmonary fibrosis, organizing pneumonia, drug-caused lung inflammation, active tuberculosis, or unexplained lung inflammation (confirm with trial site).
  • You have had certain liver treatments — such as alcohol ablation, chemoembolization, radiation to the liver, or similar procedures — within the last 3 months before the trial starts.
  • You are currently taking or have recently taken (within approximately 3 weeks) certain medications, including cancer chemotherapy, other immune therapies, or high-dose steroids not related to managing a side effect.
  • You have received a live vaccine within 28 days before the trial starts.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Robert CG Martin, MD, PhD, University of Louisville

Phone: 502-629-3355

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Robert C. Martin
Registry
ClinicalTrials.gov
Start date
24 July 2024
Est. completion
1 December 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recurrence Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov